Axsome Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
-
3.50
20.50
42.60
48.90
Gross Income
-
-
3.50
20.50
42.60
48.90
SG&A Expense
1,839.40
5,672.00
9,192.70
27,523.00
27,121.80
32,797.60
EBIT
1,839.40
5,672.00
-
27,543.50
27,164.30
32,846.60
Unusual Expense
-
2,746.00
2,278.30
-
646.00
2,791
Interest Expense
327.20
-
736.00
132.40
1,340.20
1,127.30
Pretax Income
2,166.60
6,184.70
12,210.60
27,675.90
29,150.50
31,182.90
Income Tax
-
184.10
-
474.30
207.10
217.40
Consolidated Net Income
2,166.60
6,000.60
12,210.60
27,201.70
28,943.40
30,965.50
Net Income
2,166.60
6,000.60
12,210.60
27,201.70
28,943.40
30,965.50
Net Income After Extraordinaries
2,166.60
6,000.60
12,210.60
27,201.70
28,943.40
30,965.50
Net Income Available to Common
2,166.60
6,000.60
12,210.60
27,201.70
28,943.40
30,965.50
EPS (Basic)
0.11
0.30
1.02
1.42
1.27
1.15
Basic Shares Outstanding
19,987.10
19,987.10
11,945.30
19,150.70
22,764.60
26,883.70
EPS (Diluted)
0.11
0.30
1.02
1.42
1.27
1.15
Diluted Shares Outstanding
19,987.10
19,987.10
11,945.30
19,150.70
22,764.60
26,883.70
EBITDA
1,839.40
5,672.00
9,192.70
27,523.00
27,121.80
32,797.70
Non-Operating Interest Income
-
2,233.30
-
-
-
-
About Axsome Therapeutics
View Profile
